CPIG
IBRX icon

Chicago Partners Investment Group’s ImmunityBio IBRX Stock Holding History

Chicago Partners Investment Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$169K Sell
22,901
-53
-0.2% -$401 ﹤0.01% 1447
2026
Q1 		$185K Sell
22,954
-1,694
-7% -$11.6K ﹤0.01% 1354
2025
Q4 		$159K Buy
24,648
+172
+0.7% +$390 ﹤0.01% 1249
2025
Q3 		$63.1K Sell
24,476
-2,107
-8% -$5.43K ﹤0.01% 1197
2025
Q2 		$79.5K Buy
+26,583
New +$71.5K ﹤0.01% 1069

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Chicago Partners Investment Group's IBRX Position: Q2 2026 in Review

Chicago Partners Investment Group reduced its ImmunityBio (IBRX) stake by 0.23% in Q2 2026, selling an estimated $401 and leaving 22,901 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #1447.

Chicago Partners Investment Group first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $185K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Chicago Partners Investment Group held 22,901 shares of ImmunityBio worth $169K as of Q2 2026.
  • Chicago Partners Investment Group sold 53 ImmunityBio shares in Q2 2026, an estimated $401.
  • ImmunityBio made up ﹤0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #1447 holding.
  • Chicago Partners Investment Group first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • Chicago Partners Investment Group's ImmunityBio position peaked at $185K in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.